BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 30

• Drug Development

  ZS Pharma Announces Positive Interim Results From A Long-Term Safety Study Of ZS-9

  November 9, 2015

   · 

  8 min read
• Biotech Bay

  Guardant Health And Collaborators Present Further Clinical Utility Data For Guardant360 At The AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics

  November 9, 2015

   · 

  6 min read
• Policy

  ScinoPharm Changshu Site Completed US FDA Inspection

  November 9, 2015

   · 

  3 min read
• Drug Development

  CLI Data From Cesca Therapeutics’s Phase I/Phase II And Feasibility Studies To Be Presented At The American Heart Association-Scientific Sessions Conference By Richard Powell, M.D.

  November 9, 2015

   · 

  5 min read
• Drug Development

  aTyr Pharma Initiates Phase 1b/2 Clinical Trial In Patients With Early Onset FSHD

  November 9, 2015

   · 

  6 min read
• Lone Star Bio

  Xbiotech Announces Positive Results For Its Anti-Ebola Therapeutic Candidates Following Evaluation By USAMRIID

  November 9, 2015

   · 

  5 min read
• Policy

  Collegium Announces FDA Tentative Approval For Xtampza(TM) ER, A Novel Abuse-Deterrent Analgesic For Chronic Pain

  November 9, 2015

   · 

  5 min read
• FDA

  RedHill Biopharma Ltd. And IntelGenx Corp. Announce First European Marketing Approval Of RIZAPORT (RHB-103) For Migraines

  November 9, 2015

   · 

  10 min read
• Drug Development

  Sunesis Presents Preclinical Data From Its BTK And PDK1 Inhibitor Programs At The AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics

  November 9, 2015

   · 

  7 min read
• Drug Development

  PhaseBio Announces Initiation Of Phase IIa Multiple Ascending Dose Study Of Once-Weekly Basal Insulin PE0139 In Type 2 Diabetes

  November 9, 2015

   · 

  2 min read